We're excited to share that Charles has been appointed as a full time member of the Children's Oncology Group (COG) Soft Tissue Sarcoma Committee. This committee designs clinical and translational trials for rhabdomyosarcoma and other soft tissue sarcomas. This appointment follows other COG activities in recent years including ad hoc participation in the Soft Tissue Sarcoma Committee since 2001. Also, Charles has also been an awardee of the COG Young Investigator Award (2001) and a recipient of the COG Translational Research Award (2001-2002). The results of the latter are published as a COG report entitled, "Rhabdomyosarcomas utilize developmental, myogenic growth factors for disease advantage". This study was the foundation upon which our more recent from-the-bench-towards-bedside efforts have been focused. Our lab looks forward to being able to contribute more to clinical and translational trial design as new, molecularly-targeted drugs become available to pediatric patients.